Bullish
$VSTM I repeat! 1) Investors should know that 89% of all companies with a single approved oncology drug (so called, “Singlets’”) eventually got bought out (Kinch, 2015)🧠💰💥💥💥 2) The Dana Farber Doctor Mathew Davids, MD mentioned that ‘This oral regimen with only 1 year of therapy, could become 1 of the preferred approaches for relapsed/ refractory CLL’💥 3) Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax shows Promising Responses in Richter Syndrome-PDX Models. 4) Watch for PTCL Breakthrough Designation in 2020 5) CH & Defactinib work well in combo💥
  • 15
  • 3